WuXiBody is a novel bispecific antibody (bsAb) platform developed by WuXi Biologics. It enables almost any monoclonal antibody (mAb) sequence pair to be assembled into a bispecific construct. BsAbs based on WuXiBody can adopt either asymmetric or symmetric format. WuXiBody's unique design not only ensures desired chain pairing but also facilitates removal of potential product-related impurities. In this work, demonstrated with four WuXiBody-based bsAbs (two asymmetric and two symmetric ones), we showed that Protein A followed by anion exchange (AEX) and mixed-mode chromatography (i.e., Capto MMC ImpRes or Capto adhere ImpRes) can be a potential platform approach for WuXiBody purification.

中文翻译：

---

基于WuXiBody的IgG样双特异性抗体的潜在下游平台方法。

WuXiBody是由WuXi Biologics开发的新型双特异性抗体（bsAb）平台。它使几乎任何单克隆抗体（mAb）序列对都可以组装成双特异性构建体。基于WuXiBody的BsAb可以采用非对称或对称格式。WuXiBody的独特设计不仅确保了所需的链对，而且还有助于去除潜在的产品相关杂质。在这项工作中，用基于WuXiBody的四种bsAb（两个不对称和两个对称的bsAb）进行了证明，我们证明了蛋白A继之以阴离子交换（AEX）和混合模式色谱（即Capto MMC ImpRes或Capto粘附ImpRes）是可以WuXiBody纯化的潜在平台方法。